For the establishment of a successful infection, ie, long-term parasitism and a complete life
cycle, parasites use various diverse mechanisms and factors, which they may be inherently …

Trypanosoma cruzi, the agent of the American Trypanosomiasis, Chagas disease, contains
cysteine, serine, threonine, aspartyl and metallo peptidases. The most abundant among …

The cysteine protease cruzipain is essential for the viability, infectivity, and virulence of
Trypanosoma cruzi, the causative agent of Chagas disease. Thus, inhibitors of cruzipain are …

This review aims to present different aspects related to cruzipain, one of the most important
proteins of the etiological agent of Chagas disease that has been extensively studied in the …

Chagas disease and human African trypanosomiasis are endemic conditions in Latin
America and Africa, respectively, for which no effective and safe therapy is available. Efforts …

The aim of this review is to gather the current knowledge of Trypanosoma cruzi's virulence
factors described to date in an integrative way, relating these with the parasite's life cycle …

Trypanosoma cruzi, the agent of the American Trypanosomiasis, Chagas disease, and
Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, the agents of …

The development of cruzipain inhibitors represents one of the most attractive challenges in
the search for drugs for the treatment of Chagas disease. A recombinant form of this enzyme …

Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas
disease is described. The identified inhibitors bearing an amino nitrile warhead in P1 exhibit …

More than 10 million people are thought to be infected with Trypanosoma cruzi, primarily in
the Americas. The clinical manifestations of Chagas' disease (CD) are variable, but most …